vs

Side-by-side financial comparison of COMPX INTERNATIONAL INC (CIX) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.

COMPX INTERNATIONAL INC is the larger business by last-quarter revenue ($37.7M vs $37.2M, roughly 1.0× GYRE THERAPEUTICS, INC.). COMPX INTERNATIONAL INC runs the higher net margin — 12.4% vs -3.7%, a 16.1% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -1.9%). COMPX INTERNATIONAL INC produced more free cash flow last quarter ($11.4M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs -0.4%).

COMPX International Inc. is a diversified manufacturer of security and control products, including high-performance locking systems, electronic access solutions, ergonomic workstation components, and marine hardware. It primarily serves North American and European markets, catering to commercial, residential, industrial, healthcare, and recreational marine segments.

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

CIX vs GYRE — Head-to-Head

Bigger by revenue
CIX
CIX
1.0× larger
CIX
$37.7M
$37.2M
GYRE
Growing faster (revenue YoY)
GYRE
GYRE
+35.3% gap
GYRE
33.4%
-1.9%
CIX
Higher net margin
CIX
CIX
16.1% more per $
CIX
12.4%
-3.7%
GYRE
More free cash flow
CIX
CIX
$17.2M more FCF
CIX
$11.4M
$-5.8M
GYRE
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
-0.4%
CIX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CIX
CIX
GYRE
GYRE
Revenue
$37.7M
$37.2M
Net Profit
$4.7M
$-1.4M
Gross Margin
32.1%
95.3%
Operating Margin
15.0%
0.3%
Net Margin
12.4%
-3.7%
Revenue YoY
-1.9%
33.4%
Net Profit YoY
3.6%
-340.1%
EPS (diluted)
$0.38
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CIX
CIX
GYRE
GYRE
Q4 25
$37.7M
$37.2M
Q3 25
$40.0M
$30.6M
Q2 25
$40.4M
$26.8M
Q1 25
$40.3M
$22.1M
Q4 24
$38.4M
$27.9M
Q3 24
$33.7M
$25.5M
Q2 24
$35.9M
$25.2M
Q1 24
$38.0M
$27.2M
Net Profit
CIX
CIX
GYRE
GYRE
Q4 25
$4.7M
$-1.4M
Q3 25
$4.2M
$5.9M
Q2 25
$5.5M
$1.6M
Q1 25
$5.1M
$3.7M
Q4 24
$4.5M
$569.0K
Q3 24
$3.5M
$2.9M
Q2 24
$4.8M
$4.5M
Q1 24
$3.8M
$9.9M
Gross Margin
CIX
CIX
GYRE
GYRE
Q4 25
32.1%
95.3%
Q3 25
27.6%
94.7%
Q2 25
31.9%
95.7%
Q1 25
30.2%
95.9%
Q4 24
28.8%
95.8%
Q3 24
28.1%
96.2%
Q2 24
31.1%
96.9%
Q1 24
25.5%
96.4%
Operating Margin
CIX
CIX
GYRE
GYRE
Q4 25
15.0%
0.3%
Q3 25
11.9%
22.7%
Q2 25
15.7%
8.1%
Q1 25
14.6%
10.3%
Q4 24
12.7%
2.4%
Q3 24
9.9%
16.6%
Q2 24
14.2%
12.7%
Q1 24
9.8%
29.7%
Net Margin
CIX
CIX
GYRE
GYRE
Q4 25
12.4%
-3.7%
Q3 25
10.6%
19.4%
Q2 25
13.5%
5.9%
Q1 25
12.7%
16.9%
Q4 24
11.7%
2.0%
Q3 24
10.3%
11.2%
Q2 24
13.5%
18.0%
Q1 24
9.9%
36.6%
EPS (diluted)
CIX
CIX
GYRE
GYRE
Q4 25
$0.38
$-0.01
Q3 25
$0.34
$0.03
Q2 25
$0.44
$0.00
Q1 25
$0.42
$0.00
Q4 24
$0.37
$0.00
Q3 24
$0.28
$0.01
Q2 24
$0.39
$0.01
Q1 24
$0.31
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CIX
CIX
GYRE
GYRE
Cash + ST InvestmentsLiquidity on hand
$54.1M
$52.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$138.6M
$106.0M
Total Assets
$156.2M
$166.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CIX
CIX
GYRE
GYRE
Q4 25
$54.1M
$52.4M
Q3 25
$46.3M
$60.0M
Q2 25
$56.2M
$54.4M
Q1 25
$56.1M
$29.9M
Q4 24
$60.8M
$26.7M
Q3 24
$58.8M
$25.1M
Q2 24
$82.1M
$25.1M
Q1 24
$75.6M
$37.4M
Stockholders' Equity
CIX
CIX
GYRE
GYRE
Q4 25
$138.6M
$106.0M
Q3 25
$137.7M
$101.9M
Q2 25
$149.5M
$92.0M
Q1 25
$147.6M
$68.1M
Q4 24
$146.1M
$63.3M
Q3 24
$145.3M
$63.2M
Q2 24
$170.2M
$60.4M
Q1 24
$168.9M
$56.6M
Total Assets
CIX
CIX
GYRE
GYRE
Q4 25
$156.2M
$166.1M
Q3 25
$153.7M
$159.4M
Q2 25
$164.8M
$152.6M
Q1 25
$162.2M
$129.8M
Q4 24
$163.0M
$125.4M
Q3 24
$160.1M
$125.2M
Q2 24
$185.1M
$120.9M
Q1 24
$181.7M
$122.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CIX
CIX
GYRE
GYRE
Operating Cash FlowLast quarter
$12.0M
$-5.6M
Free Cash FlowOCF − Capex
$11.4M
$-5.8M
FCF MarginFCF / Revenue
30.3%
-15.5%
Capex IntensityCapex / Revenue
1.6%
0.4%
Cash ConversionOCF / Net Profit
2.57×
TTM Free Cash FlowTrailing 4 quarters
$19.1M
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CIX
CIX
GYRE
GYRE
Q4 25
$12.0M
$-5.6M
Q3 25
$6.3M
$4.7M
Q2 25
$4.7M
$2.1M
Q1 25
$-137.0K
$-129.0K
Q4 24
$7.3M
$-2.8M
Q3 24
$4.1M
$1.7M
Q2 24
$9.8M
$-5.5M
Q1 24
$1.7M
$2.9M
Free Cash Flow
CIX
CIX
GYRE
GYRE
Q4 25
$11.4M
$-5.8M
Q3 25
$5.3M
$4.0M
Q2 25
$3.4M
$1.8M
Q1 25
$-959.0K
$-251.0K
Q4 24
$7.1M
$-2.8M
Q3 24
$3.6M
$1.0M
Q2 24
$9.4M
$-6.9M
Q1 24
$1.4M
$2.7M
FCF Margin
CIX
CIX
GYRE
GYRE
Q4 25
30.3%
-15.5%
Q3 25
13.2%
13.1%
Q2 25
8.4%
6.8%
Q1 25
-2.4%
-1.1%
Q4 24
18.5%
-10.1%
Q3 24
10.8%
4.1%
Q2 24
26.2%
-27.5%
Q1 24
3.6%
9.8%
Capex Intensity
CIX
CIX
GYRE
GYRE
Q4 25
1.6%
0.4%
Q3 25
2.5%
2.2%
Q2 25
3.3%
1.0%
Q1 25
2.0%
0.6%
Q4 24
0.6%
0.2%
Q3 24
1.4%
2.7%
Q2 24
1.2%
5.8%
Q1 24
0.8%
0.9%
Cash Conversion
CIX
CIX
GYRE
GYRE
Q4 25
2.57×
Q3 25
1.48×
0.79×
Q2 25
0.87×
1.32×
Q1 25
-0.03×
-0.03×
Q4 24
1.62×
-4.85×
Q3 24
1.18×
0.60×
Q2 24
2.03×
-1.21×
Q1 24
0.45×
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CIX
CIX

Security Products$29.5M78%
Marine Components$8.2M22%

GYRE
GYRE

Segment breakdown not available.

Related Comparisons